Table 1 Patients characteristics
Right-sided BC (N = 81) | Left-sided BC (N = 101) | All (N = 182) | P-value | |
|---|---|---|---|---|
Year of cancer diagnosis, N (%) | ||||
1995–2001 | 21 (25.9) | 31 (30.7) | 52 (28.6) | 0.76 |
2002–2008 | 37 (45.7) | 41 (40.6) | 78 (42.9) | |
2009–2012 | 23 (28.4) | 29 (28.7) | 52 (28.6) | |
Age at cancer diagnosis, N (%) | ||||
40–49 yrs | 4 (4.9) | 6 (5.9) | 10 (5.5) | 0.90 |
50–59 yrs | 19 (23.5) | 27 (26.7) | 46 (25.3) | |
60–69 yrs | 41 (50.6) | 44 (43.6) | 85 (46.7) | |
70–79 yrs | 15 (18.5) | 22 (21.8) | 37 (20.3) | |
80–83 yrs | 2 (2.5) | 2 (2.0) | 4 (2.2) | |
Age at diagnosis, median (min-max) | 64 (40–84) | 64 (44–82) | 64 (40–84) | |
Type of surgery, N (%) | ||||
Breast conserving surgery | 67 (83.8) | 88 (87.0) | 155 (85.2) | 0.79 |
Mastectomy | 13 (16.2) | 11 (12.0) | 24 (13.1) | |
No surgery | 0 (0.0) | 1 (1.0) | 1 (0.5) | |
Missing data | 1 (1.2) | 1 (1.0) | 2 (1.1) | |
Endocrine therapy, N (%) | ||||
Endocrine therapy | 44 (54.3) | 52 (51.5) | 96 (52.7) | 0.77 |
No endocrine therapy | 37 (45.7) | 49 (48.5) | 86 (47.3) | |
Chemotherapy, N (%) | ||||
Chemotherapy | 23 (28.4) | 18 (17.8) | 41 (22.5) | 0.11 |
No chemotherapy | 58 (71.6) | 83 (82.2) | 141 (77.5) | |
CT-scan slice thickness, N (%) | ||||
< 5 mm | 19 (23.5) | 20 (19.8) | 39 (21.4) | 0.92 |
5 mm | 21 (25.9) | 28 (27.7) | 49 (26.9) | |
6–9 mm | 14 (17.3) | 20 (19.8) | 34 (18.7) | |
10 mm | 25 (30.9) | 33 (32.7) | 60 (32.9) | |
15–16 mm | 2 (2.5) | 0 (0) | 2 (1.1) | |
Treatment planning system, N (%) | ||||
TMS | 47 (58.0) | 59 (58.4) | 106 (58.2) | 1.0 |
Oncentra | 8 (9.9) | 9 (8.9) | 17 (9.3) | |
Eclipse | 26 (32.1) | 33 (32.7) | 59 (32.4) | |
Algorithm, N (%) | ||||
AAA | 47 (58.0) | 60 (59.4) | 107 (58.8) | 0.20 |
CC | 21 (25.9) | 33 (32.7) | 54 (29.7) | |
PB | 13 (16.0) | 8 (7.9) | 21 (11.5) | |
Target, N (%) | ||||
Breast | 60 (74.1) | 80 (79.2) | 140 (76.9) | 0.82 |
Breast + regional LN | 8 (9.9) | 9 (8.9) | 17 (9.3) | |
Breast + regional LN + IMC | 0 (0.0) | 1 (1.0) | 1 (0.5) | |
Chest wall | 1 (1.2) | 1 (1.0) | 2 (1.1) | |
Chest wall + regional LN | 10 (12.3) | 7 (6.9) | 17 (9.3) | |
Chest wall + regional LN + IMC | 2 (2.5) | 3 (3.0) | 5 (2.7) | |
Fractionation, N (%) | ||||
2.66 Gy × 16 | 16 (19.8) | 3 (3.0) | 19 (10.4) | 0.001 |
2.67 Gy × 15 | 2 (2.5) | 1 (1.0) | 3 (1.6) | |
2 Gy x (22–24) | 3 (3.7) | 2 (2.0) | 5 (2.7) | |
2 Gy x (22–24) + boost 2 Gy × 9 | 0 (0.0) | 1 (1.0) | 1 (0.5) | |
2 Gy x (26–28) | 10 (12.3) | 8 (7.9) | 18 (9.9) | |
2 Gy × 25 | 47 (58.0) | 83 (82.2) | 130 (71.4) | |
2 Gy × 25 + boost 2 Gy × 5 | 2 (2.5) | 1 (1.0) | 3 (1.6) | |
2 Gy × 25 + boost 2 Gy × 8 | 1 (1.2) | 2 (2.0) | 3 (1.6) | |
Time from RT to SCAAR registration, N (%) | ||||
< 2 yrs | 22 (27.2) | 29 (28.7) | 51 (28.0) | 0.85 |
2–4 yrs | 15 (18.5) | 22 (21.8) | 37 (20.3) | |
4–8 yrs | 21 (25.9) | 27 (26.7) | 48 (26.4) | |
8+ yrs | 23 (28.4) | 23 (22.8) | 46 (25.3) | |
Time in years from RT to SCAAR registration, median (min-max) | 4.9 (0.1–15.6) | 3.9 (0.1–14.0) | 5.0 (0.1–15.6) | |